ALS research already benefiting from Ice Bucket Challenge's return

WCVB Boston - 21 hours ago
For patients like Bobby Forster,...

Wide Kate Lens Up-dip Intercept: 34.0m @ 20.8% ZnEq[1]

Stockhouse - 21 hours ago
Sydney, Australia (FSCwire) -...

What have we learned from Google Fiber?

CNET - 4 days ago
In the last year, however, as...

Groupon launches restaurant delivery service

Nation's Restaurant News - 5 days ago
Deal promoter Groupon has launched...

Local Art, Music and Tech Collective 20Mission Transforms The Village - 5 days ago
While 20Mission has always used...

US Jets to Use Turkish Bases in War on ISIS

New York Times - 2 weeks ago
The developments ended a...

Providence St. Vincent Stroke Care Recognized Among Best in the Country

Benzinga - 1 day ago
They know every second counts. And...

On 50th Anniversary, Medicare and Medicaid Still Vital

Forward Times - 6 days ago
Today, Medicare covers seniors,...

Local attorneys continue legal services traditions

Walker Pilot Independent - 6 days ago
Local attorney Frank Bibeau was...

Medicare, Medicaid Still Vital - 6 days ago
Originally intended for children,...

News via Google. See more news matching 'als expanded access'


Expanded Access

Bringing Research and Patients Together

Our Expanded Access platform is meant to do two things:

  1. Empower patients with access to new treatments that are in clinical research.
  2. Empower further research with clinical data from those patients.

For someone with a quick-killer disease, participating in clinical research may be the only way to access a new medicine that might help him live longer.  He may be willing to accept some uncertainty, considering the alternative.  So for patients, there’s a lot of overlap between treatment exploration and research.

But what about patients who cannot get into clinical trials?  Can they still take part in research and explore investigational treatment?

Yes, they can, but only through what are called Expanded Access programs (EAPs).  These are meant to include a much broader group of patients than traditional clinical trials, sometimes exclusively those patients who don’t meet clinical trial enrollment criteria or who otherwise cannot get into trials.

ALS-ETF is bringing a new kind of Expanded Access to the ALS community, to make a groundbreaking impact in the treatment landscape for patients as well as the research that’s powered by patient data.

Learn more about Expanded Access programs here.

Learn more about our research goals here.